Progressive Familial Intrahepatic Cholestasis
15
6
6
6
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 15 trials
100.0%
+13.5% vs benchmark
7%
1 trials in Phase 3/4
17%
1 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (15)
A Study of the Effectiveness, Safety and the Long-term Outcomes of Participants With Progressive Familial Intrahepatic Cholestasis (PFIC) Who Take Odevixibat (Bylvay) in South Korea
Long Term Safety & Efficacy Study Evaluating The Effect of A4250 in Children With PFIC
DEFINING THE GENETIC DRIVERS OF ADULT-ONSET CHOLESTATIC LIVER DISEASE
Baby Detect : Genomic Newborn Screening
Long-Term SafEty and Clinical Outcomes of LivmArli in Patients in the United States (LEAP-US)
A Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Participants With Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome (ALGS).
Prospective Analysis of the Treatment of Progressive Familial Intrahepatic Cholestasis (TreatFIC)
NAtural Course and Prognosis of PFIC and Effect of Biliary Diversion
Genotype-phenotype Relationship Between Cryptogenic Cholestasis and Familial Intrahepatic Cholestasis
Progressive Familial Intrahepatic Cholestasis in Indian Children - Establishing an Indian PFIC Registry
A Safety and Pharmakokinetic Study of A4250 Alone or in Combination With A3384
Odevixibat for the Treatment of Progressive Familial Intrahepatic Cholestasis
An Open Label, Single-dose, Single Period ADME Study of A4250 in Healthy Subjects
Gastrostomy-Biliary Diversion: Innovative Management for Bile Canalicular Transport Disorders
Validation of the Itch Reported Outcome (ItchRO) Diaries in Pediatric Cholestatic Liver Disease